Conditions:  Advanced Solid Tumor;  Gynecologic Cancer;  Breast Cancer;  Colorectal Cancer;  Gastric Adenocarcinoma;  Lung Adenocarcinoma;  Pancreatic Cancer;  Head and Neck Cancer
Interventions:  Drug: PY159 Single agent dose level 1;  Drug: PY159 Single agent dose level 2;  Drug: PY159 Single agent dose level 3;  Drug: PY159 Single agent dose level 4;  Drug: PY159 Single agent dose level 5;  Drug: PY159 Single agent dose level 6;  Drug: PY159 Single agent dose level 7;  Drug: PY159/Pembrolizumab Combination dose level 1;  Drug: PY159/Pembrolizumab Combination dose level 2;  Drug: PY159/Pembrolizumab Combination dose level 3;  Drug: PY159/Pembrolizumab Combination dose level 4;  Drug: PY159 Single agent dose expansion cohort;  Drug: PY159/Pembrolizumab Combination dose expansion cohort 1;  Drug: PY159/Pembrolizumab Combination dose expansion cohort 2;  Drug: PY159/Pembrolizumab Combination dose expansion cohort 3;  Drug: PY159/Pembrolizumab Combination dose expansion cohort 4;  Drug: PY159/Pembrolizumab Combination dose expansion cohort 5;  Drug: PY159/Pembrolizumab Combination dose expansion cohort 6
Sponsors:  Pionyr Immunotherapeutics Inc.;  Gilead Sciences
**RECRUITING NOW**
Interventions:  Drug: PY159 Single agent dose level 1;  Drug: PY159 Single agent dose level 2;  Drug: PY159 Single agent dose level 3;  Drug: PY159 Single agent dose level 4;  Drug: PY159 Single agent dose level 5;  Drug: PY159 Single agent dose level 6;  Drug: PY159 Single agent dose level 7;  Drug: PY159/Pembrolizumab Combination dose level 1;  Drug: PY159/Pembrolizumab Combination dose level 2;  Drug: PY159/Pembrolizumab Combination dose level 3;  Drug: PY159/Pembrolizumab Combination dose level 4;  Drug: PY159 Single agent dose expansion cohort;  Drug: PY159/Pembrolizumab Combination dose expansion cohort 1;  Drug: PY159/Pembrolizumab Combination dose expansion cohort 2;  Drug: PY159/Pembrolizumab Combination dose expansion cohort 3;  Drug: PY159/Pembrolizumab Combination dose expansion cohort 4;  Drug: PY159/Pembrolizumab Combination dose expansion cohort 5;  Drug: PY159/Pembrolizumab Combination dose expansion cohort 6
Sponsors:  Pionyr Immunotherapeutics Inc.;  Gilead Sciences
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
